Dec 22 (Reuters) - Novelion Therapeutics Inc NVLN.TO
* Novelion Therapeutics - unit submitted MAA to EMA seeking approval for metreleptin as replacement therapy to treat complications of leptin deficiency
* Novelion Therapeutics Inc - company, through its subsidiary, will seek to market metreleptin in EU under tradename myalepta Source text for Eikon: ID:nGNXNNPVOa Further company coverage: NVLN.TO